Professor Jutta Heim has joined Nuevolution, a small molecule lead discovery firm based in Copenhagen, Denmark, as Director and Senior Scientific Advisor to the Board of Directors.
Heim previously worked for more than 20 years at Ciba-Geigy/Novartis in Switzerland and the US. At Novartis, she was involved in the development and launch of anti-thrombotic and fibrinolytic products. She established Novartis’ molecular genetics department in oncology, became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. Heim completed her career at Novartis heading the Novartis Lead Discovery Centre with worldwide responsibility.
From 2004 to 2009, Heim was CSO at Basilea Pharmaceutica, a Swiss biopharmaceutical company focusing on anti-infectives, inflammation and oncology. From 2009 to 2013, she was CTO and CSO at Evolva.
Nuevolution's board now includes Heim plus:
- Stig Løkke Pedersen, Chairman
- Viktor Drvota, Director, SEB Venture Capital, Head of Investment Area, Life Science
- Søren Lemonius, Director, Partner, Sunstone Capital
- Jonas Brambeck, Director, Investment Manager, Industrifonden.
- Stefan Olofsson, Observer, SEB Venture Capital Investment Manager, Life Science and Technology
In June 2012, Nuevolution announced a new financing round of €11m to establish an internal pipeline of drug candidates addressing important targets within oncology and inflammation.
The firm says Heim's appointment represents an integrated part of the overall strategy to strengthen the expertise of the company at all levels.
